Zevra Therapeutics Q4 2023 GAAP EPS $(0.40) Misses $(0.27) Estimate, Sales $13.217M Beat $11.738M Estimate

Zevra Therapeutics Inc Ordinary Shares +0.44%

Zevra Therapeutics Inc Ordinary Shares

ZVRA

4.52

+0.44%

Zevra Therapeutics (NASDAQ: ZVRA) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.27) by 48.15 percent. The company reported quarterly sales of $13.217 million which beat the analyst consensus estimate of $11.738 million by 12.60 percent. This is a 474.65 percent increase over sales of $2.300 million the same period last year.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via